CONTENTS

Special Lecture

1079 There Are No Bad Anticancer Agents, Only Bad Clinical Trial Designs—Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Daniel D. Von Hoff.

Review Article


Advances in Brief


Research Articles


1147 Infrequent Expression of p21 Is Related to Altered p53 Protein in Pancreatic Carcinoma. Yu-Xin Hu, Hirokazu Watanabe, Koushiro Ohtsuno, Yasushi Yamaguchi, Aiguli Ha, Yoshiharu Motoo, Takashi Okai, and Norio Sawabu.


1193 Phase I Study of Suramin Combined with Doxorubicin in the Treatment of Androgen-independent Prostate Cancer. Shi-Ming Tu, Lance C. Paghiaro, Marie E. Banks, Robert J. Amato, Randall E. Millikan, Nagla A. Bugazia, Timothy Madden, Robert A. Newman, and Christopher J. Logothetis.

1203 A Two-Part Phase I Trial of High-Dose Interleukin 2 in Combination with Soluble (Chinese Hamster Ovary) Interleukin 1 Receptor. David F. McDermott, Elizabeth G. Trehu, James W. Mier, Damian Source, William Rand, Lucie Ronayne, Kerry Kappler, Marguerite Clancy, Mark Klempner, and Michael B. Atkins.


Patients with Isolated Trisomy 8 in Acute Myeloid Leukemia Are Not Cured with Cytarabine-based Chemotherapy: Results from Cancer and Leukemia Group B 8461. John C. Byrd, David Lawrence, Diane C. Arthur, Mark J. Pettenati, Ramana Tantravahi, Mazin Qumsiyeh, Judith Stamberg, Frederick R. Davey, Charles A. Schiffer, and Clara D. Bloomfield.


Loss of p21WAF1/Cip1 Protein Expression Accompanies Progression of Sporadic Colorectal Neoplasms but not Hereditary Nonpolyposis Colorectal Cancers. Frank A. Sinicrope, Gardiner Roddey, Michael Lemoine, Sanbao Ruan, L. Clifton Stephens, Marsha L. Frazier, Yu Shen, and Wei Zhang.


